Recursion Pharmaceuticals, Inc (RXRX)
NASDAQ:RXRX
Want to see RXRX full AI Analyst Report?
RXRX Stock Chart & Stats
$3.78
-$0.34(-4.54%)
At close: 4:00 PM EST
$3.78
-$0.34(-4.54%)
Day’s Range― - ―
52-Week Range$2.77 - $7.18
Previous CloseN/A
Volume5.68M
Average Volume (3M)18.97M
Market Cap
$1.67B
Enterprise Value$1.02B
Total Cash (Recent Filing)$654.47M
Total Debt (Recent Filing)$72.38M
Price to Earnings (P/E)―
Beta3.33
Next Earnings
Aug 11, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.20
Shares Outstanding524,677,860
10 Day Avg. Volume22,878,004
30 Day Avg. Volume18,973,858
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.62
Price to Sales (P/S)24.50
P/FCF Ratio-4.84
Enterprise Value/Market Cap0.61
Enterprise Value/Revenue15.44
Enterprise Value/Gross Profit-44.82
Enterprise Value/Ebitda-2.13
Forecast
1Y Price Target
$7.38Price Target Upside95.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.93
Revenue Forecast (FY)$61.30M
Bulls Say, Bears Say
Bulls Say
Proprietary Data MoatRecursion’s >50 PB dataset and >10 high-dimensional biology maps create a durable data moat for ML-driven discovery. Proprietary scale improves model training, target ID, and patient stratification, increasing partner value and raising barriers for competitors over years.
Discovery EfficiencyThe platform’s claimed ~90% reduction in compounds and ~2× faster candidate progression materially lower R&D cost and time-to-proof. Sustained efficiency enables more parallel programs, better capital productivity, and higher throughput for both internal pipelines and partner collaborations long-term.
Partnership Traction & Non-dilutive FundingOver $500M of partner inflows and ten milestones show durable external monetization and big-pharma validation. Strong partner engagement provides non-dilutive capital, funds R&D, and creates optionality for downstream royalties or opt-ins, reducing funding stress if milestone timing holds.
Bears Say
Heavy Cash BurnPersistent negative operating cash flow (~-$321M TTM) and deteriorating free cash flow mean the business consumes significant cash. This increases reliance on milestone timing or external financing; delays or missed inflows could force dilutive capital raises or program curtailments, pressuring strategy.
Negative Profitability ProfileNegative gross profit and an extremely negative net margin indicate the current cost base outpaces revenue generation. Without a sustainable shift to higher-margin product revenues or larger partnership economics, the firm’s returns on invested capital will remain deeply negative and value creation is uncertain.
Clinical & Regulatory Timing RiskMany pivotal readouts are 12–18 months away and REC‑4881 faces first-in-disease regulatory uncertainty. Limited precedent complicates endpoint and trial design; adverse data or regulatory delays could postpone approvals, partner opt-ins, and revenue, amplifying funding and execution risk.
Recursion Pharmaceuticals News
RXRX FAQ
What was Recursion Pharmaceuticals, Inc’s price range in the past 12 months?
Recursion Pharmaceuticals, Inc lowest stock price was $2.77 and its highest was $7.18 in the past 12 months.
What is Recursion Pharmaceuticals, Inc’s market cap?
Recursion Pharmaceuticals, Inc’s market cap is $1.67B.
When is Recursion Pharmaceuticals, Inc’s upcoming earnings report date?
Recursion Pharmaceuticals, Inc’s upcoming earnings report date is Aug 11, 2026 which is in 56 days.
How were Recursion Pharmaceuticals, Inc’s earnings last quarter?
Recursion Pharmaceuticals, Inc released its earnings results on May 06, 2026. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.265 by $0.045.
Is Recursion Pharmaceuticals, Inc overvalued?
According to Wall Street analysts Recursion Pharmaceuticals, Inc’s price is currently Undervalued.
Does Recursion Pharmaceuticals, Inc pay dividends?
Recursion Pharmaceuticals, Inc does not currently pay dividends.
What is Recursion Pharmaceuticals, Inc’s EPS estimate?
Recursion Pharmaceuticals, Inc’s EPS estimate is -0.24.
How many shares outstanding does Recursion Pharmaceuticals, Inc have?
Recursion Pharmaceuticals, Inc has 524,677,860 shares outstanding.
What happened to Recursion Pharmaceuticals, Inc’s price movement after its last earnings report?
Recursion Pharmaceuticals, Inc reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.265. Following the earnings report the stock price went up 1.78%.
Which hedge fund is a major shareholder of Recursion Pharmaceuticals, Inc?
Currently, no hedge funds are holding shares in RXRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Recursion Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.38 (95.11% Upside)
$7.38 (95.11% Upside)
Blogger Sentiment
Bullish
RXRX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.5%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.13%
12-Months-Change
Fundamentals
Return on Equity
-54.32%
Trailing 12-Months
Asset Growth
2.63%
Trailing 12-Months
Company Description
Recursion Pharmaceuticals, Inc
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
RXRX Company Deck
RXRX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized multiple clear positives: a clinical proof of concept (REC-4881), encouraging early clinical safety/PK/PD for REC-1245, first patient dosed for REC-4539, strong partnership traction (> $500M inflows, 10 milestones), platform efficiency gains (≈90% fewer compounds, ~2x faster candidate progression), and a 30% YoY reduction in cash operating expenses with $665M cash (runway into early 2028). The primary negatives are that the programs are still early (key readouts and registrational plans pending), regulatory uncertainty for first-in-disease indications, potential safety risks as dose escalation continues, and a finite runway that could be pressured by delays. Overall, the highlights materially outweigh the lowlights given the combination of clinical proofs, platform progress, partnership milestones, and cost discipline.View all RXRX earnings summariesRXRX Stock 12 Month Forecast
Average Price Target
$7.38
▲(95.11% Upside)
Technical Analysis
Ownership Overview
2.87% Insiders
12.35% Mutual Funds
24.07% Other Institutional Investors
34.43% Public Companies and Individual Investors